• Markets
    • icon
  • Companies
CHM · ASX

Chimeric Therapeutics Limited (ASX:CHM)

AU$0.029

 0.0 (0.0%)
ASX:Live
05/12/2023 04:10:44 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CHM Overview

CHM Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About CHM

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3 62 Lygon Street Carlton South, Victoria (VIC) 3053

Description

Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. Currently it is undergoing Phase 1 clinical trials at City of Hope in glioblastoma. The company was founded by Paul A. Hopper on Feburary 2, 2020 and is headquartered in Carlton South, Australia.

CHM Price Chart

Key Stats

Market Cap

AU$16.55M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.09

Trade Value (12mth)

AU$10,857.00

1 week

-3.33%

1 month

3.57%

YTD

-65.48%

1 year

-66.28%

All time high

0.424096

Key Fundamentals

EPS 3 yr Growth

29800.000%

EBITDA Margin

N/A

Operating Cashflow

-$16m

Free Cash Flow Return

-104.00%

ROIC

-165.20%

Interest Coverage

-36.90

Quick Ratio

0.60

Other Data

Shares on Issue (Fully Dilluted)

438m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CHM Announcements

Latest Announcements

Date Announcements

31 October 23

FDA clearance of IND for CHM 2101

×

FDA clearance of IND for CHM 2101

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Change of Registry Address

×

Change of Registry Address

31 May 23

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 23

Initial Director's Interest Notice ES

×

Initial Director's Interest Notice ES

31 August 23

Final Director's Interest Notice CE

×

Final Director's Interest Notice CE

31 August 23

Appendix 4E and Preliminary Final Report

×

Appendix 4E and Preliminary Final Report

31 August 22

Appendix 4E and Preliminary Final Report

×

Appendix 4E and Preliminary Final Report

30 September 22

Corporate Governance Statement

×

Corporate Governance Statement

30 September 22

Annual Report to shareholders

×

Annual Report to shareholders

30 September 22

Appendix 4G

×

Appendix 4G

30 September 22

ESG Report

×

ESG Report

30 March 22

Appendix 2A

×

Appendix 2A

30 March 22

Change of Director's Interest Notice - LC

×

Change of Director's Interest Notice - LC

30 March 22

Change of Director's Interest Notice - PH

×

Change of Director's Interest Notice - PH

30 March 22

Change of Director's Interest Notice - CE

×

Change of Director's Interest Notice - CE

30 March 22

Change of Director's Interest Notice - GM

×

Change of Director's Interest Notice - GM

30 June 22

Change of Director's Interest Notice - LC

×

Change of Director's Interest Notice - LC

30 August 23

Non-Executive Director Board Changes

×

Non-Executive Director Board Changes

29 September 21

CHM 1101 data accepted for presentation at SNO meeting

×

CHM 1101 data accepted for presentation at SNO meeting

29 September 21

Annual Report to shareholders

×

Annual Report to shareholders

29 June 23

Results of Extraordinary General Meeting

×

Results of Extraordinary General Meeting

29 June 23

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

29 June 23

Notice under section 708A

×

Notice under section 708A

29 June 22

Licenses viral vector technology from Penn for CDH17

×

Licenses viral vector technology from Penn for CDH17

29 June 22

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

CHM Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.08 -0.04 -0.06 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.08 -0.04 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -39,950.0 44.8 -35.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17,342.6 21.0 -54.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -16.8 -39.8 -99.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.07 0.06 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 0.03 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17,770.9 -13.9 -151.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 189 360 433 Lock Lock Lock
Basic m Lock Lock Lock Lock 189 360 433 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 14 14 29 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -12.1 -1.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -14 -14 -29 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21,771.2 2.7 -109.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -15 -15 -29 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23,094.3 1.8 -102.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -15 -16 -30 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -15 -16 -26 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23,512.2 -5.2 -63.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -13 -16 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 5 1 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -5 -1 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 37 10 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -13 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25,947.0 -48.6 -23.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 22 18 5 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 37 35 22 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -22 -18 -5 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 11 9 17 Lock Lock Lock
Equity $m Lock Lock Lock Lock 25 26 6 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 25 26 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39,423.2 2.3 -78.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -41.4 -45.6 -115.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -60.1 -61.8 -457.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -118.3 -57.3 -188.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -120.6 -62.5 -165.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -70.6 -51.7 -104.0 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -2,382.1 -21.3 -36.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.6 1.3 0.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -89.2 -71.5 -94.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.1 2.3 0.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.1 2.3 0.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.9 86.8 57.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -120.2 -145.8 -111.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -41.4 -45.6 -115.8 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.5 1.4 4.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -60.1 -61.8 -457.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -60.1 -61.8 -457.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 439.2 1,295.2 2,289.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -439.2 -1,295.2 -2,289.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CHM Shortsell

Frequently Asked Questions

The current share price of Chimeric Therapeutics Limited (CHM:ASX) is AU$0.029.
The 52-week high share price for Chimeric Therapeutics Limited (CHM:ASX) is AU$0.09.
The 52-week low share price for Chimeric Therapeutics Limited (CHM:ASX)? is AU$0.03.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) has a franking level of 0%.
Chimeric Therapeutics Limited (CHM:ASX) is classified in the Healthcare.
The current P/E ratio for Chimeric Therapeutics Limited (CHM:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.